They’re Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again – Forbes
Business Insider |
They're Back! After Selling Kite, Belldegrun And Chang Seek To Change Cancer Treatment Again
Forbes Kite's product, Yescarta, was approved by the Food and Drug Administration last October, a type of therapy called CART (short for: chimeric antigen receptor T–cell). It costs $373,000 per patient, and involves a laborious process to re-engineer … A CEO who sold his last cancer drug company for $12 billion just got $300 million to do it again Ex-Kite chiefs' biotech to research 'off-the-shelf' CAR-Ts with Cellectis Former Kite Execs Team With Pfizer to Create Biotech Co. to Treat Cancer |
